Pathogenetic studies of motor fluctuations in Parkinson's disease
- PMID: 3042912
- DOI: 10.1007/978-3-7091-8954-2_1
Pathogenetic studies of motor fluctuations in Parkinson's disease
Abstract
Pharmacokinetic and pharmacodynamic mechanisms for levodopa have been studied in relation to the pathogenesis of the motor fluctuations which complicate advanced Parkinson's disease. Since levodopa clearance from the general circulation was found to be similar in patients with wearing-off or on-off phenomena and those with a stable response to levodopa, peripheral pharmacokinetic factors are unlikely to be involved. Efficacy half-time for levodopa, on the other hand, was significantly reduced in patients with mainly wearing-off fluctuations in comparison to those manifesting a stable response to oral levodopa; individuals with predominantly on-off phenomenon had an even more extreme reduction in the duration of the antiparkinsonian action of levodopa. Conversion from oral to intravenous levodopa treatment immediately stabilized plasma levodopa levels in both the wearing-off and on-off groups; motor variability also decreased, especially in those with wearing-off phenomenon. During 11 days of continuous intravenous levodopa therapy, additional reductions in motor fluctuations occurred in both groups, but at a significantly faster rate in patients with wearing-off than in those with on-off responses. These results suggest that wearing-off phenomenon may arise as a consequence of the degeneration of dopamine terminals due to natural disease progression with a resultant inability to buffer variations in levodopa availability; on-off phenomenon, may reflect additional postsynaptic dopamine receptor dysregulation, possibly in response to the resultant, nonphysiologic fluctuations in synaptic dopamine.
Similar articles
-
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.Ann Neurol. 1987 Oct;22(4):475-9. doi: 10.1002/ana.410220406. Ann Neurol. 1987. PMID: 3435068
-
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.Ann Neurol. 1987 Apr;21(4):370-6. doi: 10.1002/ana.410210409. Ann Neurol. 1987. PMID: 3579222
-
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.Ann Neurol. 1988 Sep;24(3):366-71. doi: 10.1002/ana.410240303. Ann Neurol. 1988. PMID: 3228270
-
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.Neurology. 1989 Nov;39(11 Suppl 2):7-10; discussion 19. Neurology. 1989. PMID: 2685653 Review.
-
Concentration-effect relationship of levodopa in patients with Parkinson's disease.Clin Pharmacokinet. 1995 Oct;29(4):243-56. doi: 10.2165/00003088-199529040-00004. Clin Pharmacokinet. 1995. PMID: 8549026 Review.
Cited by
-
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003. Clin Pharmacokinet. 2002. PMID: 11978145 Review.
-
Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.Drugs Aging. 1997 May;10(5):332-40. doi: 10.2165/00002512-199710050-00002. Drugs Aging. 1997. PMID: 9143854 Review.
-
Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease.Mov Disord Clin Pract. 2017 May 25;4(4):590-596. doi: 10.1002/mdc3.12489. eCollection 2017 Jul-Aug. Mov Disord Clin Pract. 2017. PMID: 30363502 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical